48 92

Cited 3 times in

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer

Authors
 Taroh Satoh  ;  Yoon-Koo Kang  ;  Yee Chao  ;  Min-Hee Ryu  ;  Ken Kato  ;  Hyun Cheol Chung  ;  Jen-Shi Chen  ;  Kei Muro  ;  Won Ki Kang  ;  Kun-Huei Yeh  ;  Takaki Yoshikawa  ;  Sang Cheul Oh  ;  Li-Yuan Bai  ;  Takao Tamura  ;  Keun-Wook Lee  ;  Yasuo Hamamoto  ;  Jong Gwang Kim  ;  Keisho Chin  ;  Do-Youn Oh  ;  Keiko Minashi  ;  Jae Yong Cho  ;  Masahiro Tsuda  ;  Mitsunobu Tanimoto  ;  Li-Tzong Chen  ;  Narikazu Boku 
Citation
 GASTRIC CANCER, Vol.23(1) : 143-153, 2020 
Journal Title
 GASTRIC CANCER 
ISSN
 1436-3291 
Issue Date
2020
Keywords
Gastric cancer ; Gastroesophageal junction cancer ; Nivolumab ; Trastuzumab
Abstract
BACKGROUND: Data on immune checkpoint inhibitor efficacy in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced gastric/gastroesophageal junction (G/GEJ) cancer are lacking. Because HER2 status was not captured in the ATTRACTION-2 trial, we used patients with prior trastuzumab use (Tmab+) as surrogate for HER2 expression status to evaluate the efficacy and safety of nivolumab as third- or later-line therapy in these patients. METHODS: In ATTRACTION-2, a randomized, double-blind, placebo-controlled, phase 3 multicenter trial, patients were randomized (2:1) to receive nivolumab (3 mg/kg) or placebo every 2 weeks until disease progression or toxicity requiring study discontinuation. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety were assessed. RESULTS: Of 493 enrolled patients, 81 (nivolumab, n = 59; placebo, n = 22) were Tmab+ and 412 (nivolumab, n = 271; placebo, n = 141) were Tmab-. In both groups, patients receiving nivolumab showed a longer median OS vs placebo (Tmab+, 8.3 [95% confidence interval, 5.3-12.9] vs 3.1 [1.9-5.3] months, hazard ratio, 0.38 [0.22-0.66]; P = 0.0006; Tmab-, 4.8 [4.1-6.0] vs 4.2 [3.6-4.9] months, 0.71 [0.57-0.88]; P = 0.0022). PFS was longer in both groups receiving nivolumab vs placebo (Tmab+, 1.6 [1.5-4.0] vs 1.5 [1.3-2.9] months, 0.49 [0.29-0.85]; P = 0.0111; Tmab-, 1.6 [1.5-2.4] vs 1.5 [1.5-1.5] months, 0.64 [0.51-0.80]; P = 0.0001). CONCLUSIONS: Nivolumab was efficacious and safe as third- or later-line therapy regardless of prior trastuzumab use in patients with advanced G/GEJ cancer.
Files in This Item:
T202000752.pdf Download
DOI
10.1007/s10120-019-00970-8
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Cho, Jae Yong(조재용) ORCID logo https://orcid.org/0000-0002-0926-1819
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/175570
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links